BioSpace News Archive

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23rd Annual Global Life Sciences Conference.

Cidara Therapeutics, Inc. announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference and Cantor Global Healthcare Conference.

Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment for its pivotal phase 3 study of CAN-2409 immunotherapy in patients with intermediate-high risk localized prostate cancer.

Spero Therapeutics, Inc. today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference

Arbutus Biopharma Corporation today announced that the Company will participate in the following upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and the Hellenic Institute for the Study of Sepsis today announce that Nature Medicine has published positive results from the investigator-sponsored Phase 3 SAVE-MORE randomized controlled trial evaluating anakinra

Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.

Aquestive Therapeutics, Inc. announced today that the management team will participate in three upcoming investor conferences in September as follows: H.C. Wainwright 23rd Annual Global Investment Conference: on demand corporate presentation available from September 13 - 15

ObsEva SA announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.